Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline
The DOI matches its Crossref record; 207 of the 207 references it cites were found in a registry or an index.
Abstract
OBJECTIVE The aim was to update The Endocrine Society Clinical Practice Guideline on Evaluation and Treatment of Adult Growth Hormone Deficiency (GHD) previously published in 2006. CONSENSUS PROCESS Consensus was guided by systematic reviews of evidence and discussions through a series of conference calls and e-mails. An initial draft was prepared by the Task Force, with the help of a medical writer, and reviewed and commented on by members of The Endocrine Society. A second draft was reviewed and approved by The Endocrine Society Council. At each stage of review, the Task Force received written comments and incorporated substantive changes. CONCLUSIONS GHD can persist from childhood or be newly acquired. Confirmation through stimulation testing is usually required unless there is a proven genetic/structural lesion persistent from childhood. GH therapy offers benefits in body composition, exercise capacity, skeletal integrity, and quality of life measures and is most likely to benefit those patients who have more severe GHD. The risks associated with GH treatment are low. GH dosing regimens should be individualized. The final decision to treat adults with GHD requires thoughtful clinical judgment with a careful evaluation of the benefits and risks specific to the individual.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GHD in particular has a wide range of test methodology and diagnostic thresholds employed across studies, despite agreement among global guidelines [26 · , 64-67] as to what constitutes deficiency.”
From Neuroendocrine Disruptions Following Head Injury (2023) · cites this paper as [65]
In the citing paper
“For the diagnosis of TBI-induced GHD, the ITT and the GHRHϩARG test are now considered as the tests of choice with similar accuracy (194,215).”
From Pituitary Dysfunction After Traumatic Brain Injury: A Clinical and Pathophysiological Approach (2015) · cites this paper as [215]
In the citing paper
“The glucagon stimulation test (GST) (1 mg glucagon im, GH measurements every 30 min until 240 min after administration) has been proposed as an alternative diagnostic because it is able to differentiate between GH-deficient and healthy subjects with a sensitivity and specificity of 100% if a peak GH of 3 g/L is considered (215, 226).”
From Pituitary Dysfunction After Traumatic Brain Injury: A Clinical and Pathophysiological Approach (2015) · cites this paper as [215]
In the citing paper
“For the ITT, peak GH response levels lower than 3 g/L indicate severe GHD in adults (if hypoglycemia is adequately reached) (194,215).”
From Pituitary Dysfunction After Traumatic Brain Injury: A Clinical and Pathophysiological Approach (2015) · cites this paper as [215]
In the citing paper
“Therefore, in the latest Endocrine Society guideline on the evaluation and treatment of adult GHD, as part of their standard clinical care, patients with severe GHD (diagnosed by appropriate dynamic tests and with relevant clinical features) were recommended individualized physiological doses of recombinant GH treatment (215).”
From Pituitary Dysfunction After Traumatic Brain Injury: A Clinical and Pathophysiological Approach (2015) · cites this paper as [215]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Gamma knife radiosurgery for trigeminal neuralgia associated with multiple sclerosis
Rogers, L., Shetter, A. G., Ponce, F. A., Fiedler, J. A., Smith, K. A., & Speiser, B. L. (2002) · Journal of neurosurgery · doi:10.3171/jns.2002.97.supplement_5.0529 · Cited by 1,773
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402 · cited 1×
“hypogonadal men received testosterone replacement (154).”
Salomon, F., Cuneo, R. C., Hesp, R., & Sönksen, P. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912283212605 · Cited by 1,326
The Role of Carotid Arterial Intima-Media Thickness in Predicting Clinical Coronary Events
Hodis, H. N., Mack, W. J., LaBree, L., Selzer, R. H., Liu, C.-R., Liu, C.-H., & Azen, S. P. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-4-199802150-00002 · Cited by 1,217 · cited 1×
“In epidemiological studies, increases in IMT have predicted the development of symptomatic coronary disease occurring approximately 8 yr after the initial measurements (137).”
Association between premature mortality and hypopituitarism
Tomlinson, J., Holden, N., Hills, R., Wheatley, K., Clayton, R., Bates, A., Sheppard, M., & Stewart, P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04006-x · Cited by 1,006
BENEFICIAL EFFECTS OF GROWTH HORMONE TREATMENT IN GH-DEFICIENT ADULTS
Jørgensen, J. O. L., Thuesen, L., Ingemann-Hansen, T., Pedersen, S. A., Jørgensen, I., Skakkebaek, N. E., & Christiansen, J. S. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92328-3 · Cited by 890
Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review
Carroll, P. V., Christ the members of Growth Hormon, E. R., Bengtsson, B. Å., Carlsson, L., Christiansen, J. S., Clemmons, D., Hintz, R., Ho, K., Laron, Z., Sizonenko, P., et al. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.2.4594 · Cited by 822
Self-citationTreatment of adults with growth hormone (GH) deficiency with recombinant human GH.
Bengtsson, B. A., Edén, S., Lönn, L., Kvist, H., Stokland, A., Lindstedt, G., Bosaeus, I., Tölli, J., Sjöström, L., & Isaksson, O. G. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.2.8432773 · Cited by 778
Clinical Aspects of Growth Hormone Deficiency in Adults
BOER, H. D., BLOK, G.-J., & DER VEEN, E. A. V. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-1-63 · Cited by 723
Cited by
Items 401–500 of 1,000
Determinants of outcome of transsphenoidal surgery for Cushing disease in a single-centre series
Serban, A. L., Sindaco, G. D., Sala, E., Carosi, G., Indirli, R., Rodari, G., Giavoli, C., Locatelli, M., Carrabba, G. G., Bertani, G., et al. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01151-1 · Cited by 18
Höybye, C., Beck-Peccoz, P., Şimşek, S., Zabransky, M., Zouater, H., Stalla, G. K., & Murray, R. D. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1839410 · Cited by 19
Growth Hormone Replacement Therapy: Transition from Adolescence to Adulthood
Geffner, M. E. (2009) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.v1i5.205 · Cited by 19
Klefter, O. N., & Feldt‐Rasmussen, U. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0160 · Cited by 20
Qing, L., Wei, R., Chan, L., Zheng, X., & Xin, X.-J. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0621-2 · Cited by 19
Recombinant Human Growth Hormone: Rationale for Use in the Treatment of HIV-Associated Lipodystrophy
Benedini, S., Terruzzi, I., Lazzarin, A., & Luzi, L. (2008) · BioDrugs · doi:10.2165/00063030-200822020-00003 · Cited by 18
Adrenogenitales Syndrom und Wachstumshormonmangel: Betreuung beim Übergang zum Erwachsenenalter
Dörr, H. G., & Schöfl, C. (2009) · Der Internist · doi:10.1007/s00108-009-2401-3 · Cited by 17
Rasmussen, M. H., Jensen, L., Anderson, T. W., Klitgaard, T., & Madsen, J. C. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03863.x · Cited by 18
Marcianò, I., Ingrasciotta, Y., Giorgianni, F., Ientile, V., Chinellato, A., Tari, D. U., Gini, R., Cannavò, S., Pastorello, M., Scondotto, S., et al. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00095 · Cited by 17
Risi, R., Masieri, S., Poggiogalle, E., Watanabe, M., Caputi, A., Tozzi, R., Gangitano, E., Masi, D., Mariani, S., Gnessi, L., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249733 · Cited by 18
Taghizadeh, B., Jaafari, M. R., & Zarghami, N. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.963336 · Cited by 20
Anterior pituitary hormone replacement therapy—a clinical review
Auernhammer, C. J., & Vlotides, G. (2007) · Pituitary · doi:10.1007/s11102-007-0001-6 · Cited by 17
Miljić, D., Miljić, P., Doknić, M., Pekić, S., Stojanović, M., Cvijović, G., Micić, D., & POPOVIC, V. M. (2013) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2013.08.005 · Cited by 17
Stawerska, R., Smyczyńska, J., Hilczer, M., & Lewiñski, A. (2017) · International Journal of Endocrinology · doi:10.1155/2017/5713249 · Cited by 17
Financial Conflicts of Interest Among Authors of Endocrine Society Clinical Practice Guidelines*
Irwig, M. S., Kyinn, M., & Shefa, M. C. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00526 · Cited by 20
Long-term growth hormone (GH) replacement of adult GH deficiency (GHD) benefits the heart
Ziagaki, A., Blaschke, D., Haverkamp, W., & Plöckinger, U. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0132 · Cited by 18
Impact of age on postsurgical outcomes of nonfunctioning pituitary adenomas
Biamonte, E., Betella, N., Milani, D., Lasio, G. B., Ariano, S. A., Radice, S., Lavezzi, E., Mazziotti, G., & Lania, A. G. (2020) · Endocrine · doi:10.1007/s12020-020-02554-4 · Cited by 18
Experience of a Pituitary Clinic for US Military Veterans With Traumatic Brain Injury
Lee, J., Anderson, L. J., Migula, D., Yuen, K. C. J., McPeak, L., & Garcia, J. M. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab005 · Cited by 17
IGF-I measurements in the monitoring of GH therapy
Higham, C., Jostel, A., & Trainer, P. J. (2007) · Pituitary · doi:10.1007/s11102-007-0027-9 · Cited by 17
Managing Transition in Patients Treated with Growth Hormone
Hauffa, B. P., Touraine, P. A., Urquhart-Kelly, T., & Koledova, E. B. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00346 · Cited by 17
Albu, D. N., & Albu, A. I. (2018) · Systems Biology in Reproductive Medicine · doi:10.1080/19396368.2018.1492044 · Cited by 17
“…the study of Rajesh et al. (2007) also reported an improved evolution of embryos after GH administration, the patients in that study were diagnosed with GHD based on clonidine stimulation test which is not accepted for evaluation in adults according to current guidelines (Molitch et al. 2011).”
BackgroundMethodAbuse of Growth Hormone Among Young Athletes
Buzzini, S. R. R. (2007) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2007.07.002 · Cited by 18
Ergun-Longmire, B., & Wajnrajch, M. P. (2013) · Europe PMC (PubMed Central) · Cited by 17
The accuracy of diagnostic tests for GH deficiency in adults: a systematic review and meta-analysis
Hazem, A., Elamin, M. B., Malaga, G., Bancos, I., Prevost, Y., Zeballos-Palacios, C., Velasquez, E. R., Erwin, P. J., Natt, N., Montori, V. M., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0476 · Cited by 16
Response to GH Treatment After Radiation Therapy Depends on Location of Irradiation
Rose, S. R., Carlsson, M. O., Grimberg, A., Aydin, F., Albanese, A., Hokken-Koelega, A., & Camacho‐Hübner, C. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa478 · Cited by 18
Hage, C., & Salvatori, R. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.10.003 · Cited by 21
Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia
Herodes, M., Anderson, L. J., Shober, S., Schur, E. A., Graf, S. A., Ammer, N., Salas, R., Marcelli, M., & Garcia, J. M. (2023) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13191 · Cited by 16
Chihara, K., Fujieda, K., Shimatsu, A., Miki, T., & Tachibana, K. (2010) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2010.01.003 · Cited by 14
“Therefore, it would be appropriate to adjust doses of GH according to serum level of IGF-I and treatment-emergent adverse drug reactions in accordance with the guidelines [5,7,21].”
BackgroundMethodSommer, G., Gianinazzi, M. E., Kuonen, R., Bohlius, J., l’Allemand, D., Hauschild, M., Mullis, P. E., Kuehni, C. E., & Swiss Society for Paediatric Endocrinology and Diabetology (SGPED) (2015) · PLoS ONE · doi:10.1371/journal.pone.0140944 · Cited by 16
“Most frequently, rhGH treatments are intended to promote growth, but rhGH therapy also improves body composition, cardiovascular outcomes, lipid profile, and bone density [1].”
BackgroundCiresi, A., Radellini, S., Guarnotta, V., & Giordano, C. S. D. S. (2016) · Endocrine · doi:10.1007/s12020-016-1076-5 · Cited by 17
“At baseline the diagnosis of GHD was established by the criteria of the Endocrine Society [18].”
MethodBerberoğlu, M., Şıklar, Z., Darendelıler, F., Poyrazoğlu, Ş., Darcan, Ş., İşgüven, P., Bıdecı, A., Öçal, G., Bundak, R., Yüksel, B., et al. (2008) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4008/jcrpe.v1i1.7 · Cited by 16
Clinical characteristics of Japanese adults with growth hormone deficiency: a HypoCCS database study
Shimatsu, A., Tai, S., Tanaka, T., Fujieda, K., Teramoto, A., & Chihara, K. (2011) · Endocrine Journal · doi:10.1507/endocrj.k10e-363 · Cited by 16
Mihaila, S. B., Mincu, R. I., Rimbaş, R. C., Dulgheru, R., Dobrescu, R., Magda, S. L., Badiu, C., & Vinereanu, D. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.01.008 · Cited by 20
Groban, L., Lin, M., Kassik, K. A., Ingram, R. L., & Sonntag, W. E. (2011) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2011.01.003 · Cited by 17
Adult-onset growth hormone deficiency: causes, complications and treatment options
Mathioudakis, N. N., & Salvatori, R. (2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3282ffd97d · Cited by 17
Bogazzi, F., Manetti, L., Lombardi, M., Giovannetti, C., Raffaelli, V., Urbani, C., Scattina, I., Pepe, P., Iannelli, A., Martino, E., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-1068 · Cited by 17
Dennis, D. P., Robertson, D. G. C., Curtis, L. T., & Black, J. (2009) · Toxicology and Industrial Health · doi:10.1177/0748233709348266 · Cited by 16
Growth Hormone: The Expansion of Available Products and Indications
Franklin, S. L., & Geffner, M. E. (2011) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2011.07.006 · Cited by 19
van Varsseveld, N. C., van Bunderen, C. C., Franken, A. A. M., Koppeschaar, H. P. F., van der Lely, A. J., & Drent, M. L. (2016) · Pituitary · doi:10.1007/s11102-016-0716-3 · Cited by 21
Kužma, M., Binkley, N., Bednárová, A., Killinger, Z., Vaňuga, P., & Payer, J. (2016) · Endocrine Practice · doi:10.4158/ep151183.or · Cited by 18
Serban, A. L., Sala, E., Carosi, G., Sindaco, G. D., Giavoli, C., Locatelli, M., Arosio, M., Mantovani, G., & Ferrante, E. (2019) · Neuroendocrinology · doi:10.1159/000496846 · Cited by 19
Meyer, S., Haist, M., Schaefer, S., Ivan, D., Ittner, J. R., Nawroth, P. P., Plöckinger, U., Stalla, G. K., Tuschy, U., Weber, M. M., et al. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.8.1017 · Cited by 16
GH Replacement in the Elderly: Is It Worth It?
Bitti, S. R., Franco, M., Albertelli, M., Gatto, F., Vera, L., Ferone, D., & Boschetti, M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.680579 · Cited by 18
Casale, M., Baldini, M., Monte, P. D., Gigante, A., Grandone, A., Origa, R., Poggi, M., Gadda, F., Lai, R., Marchetti, M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11071826 · Cited by 21
Hormonal Replacement Therapy in Heart Failure
Salzano, A., D’Assante, R., Lander, M., Arcopinto, M., Bossone, E., Suzuki, T., & Cittadini, A. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.02.007 · Cited by 15
Spaziani, M., Tarantino, C., Tahani, N., Gianfrilli, D., Sbardella, E., Isidori, A. M., Lenzi, A., & Radicioni, A. F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.634288 · Cited by 17
GH and Senescence: A New Understanding of Adult GH Action
Chesnokova, V., & Melmed, S. K. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab177 · Cited by 19
Takahashi, Y., Biller, B. M. K., Fukuoka, H., Ho, K. K. Y., Rasmussen, M. H., Nedjatian, N., Sværke, C., Yuen, K. C. J., & Johannsson, G. (2022) · Pituitary · doi:10.1007/s11102-022-01283-3 · Cited by 18
“Growth hormone replacement therapy (GHRT) in AGHD improves body composition (reduced fat mass, increased lean mass and muscle strength), bone mineral density and cardiovascular risk markers (increased high-density lipoprotein cholesterol and reductions in low-density lipoprotein cholesterol, C-reactive protein, diasto…”
BackgroundModesto, M. J., Amer, N. M., Erichsen, O., Hernández, S., dos Santos, C. N. D., de Carvalho, J. Â. R., Pereira, R. M., Nesi-França, S., & de Lacerda, L. (2014) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2013-0317 · Cited by 16
Park, K. D., Lim, O. K., Yoo, C. J., Kim, Y. W., Lee, S., Park, Y., & Lee, J. K. (2016) · Brain Injury · doi:10.3109/02699052.2015.1127997 · Cited by 17
Chihara, K., Kato, Y., Kohno, H., Takano, K., Tanaka, T., Teramoto, A., & Shimatsu, A. (2008) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2007.12.001 · Cited by 15
van Bunderen, C. C., Lips, P. T. A. M., Kramer, M. H. H., & Drent, M. L. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.03.026 · Cited by 17
“The target level commonly is the upper half of that range, although published studies do not offer specific guidance in this regard.(17) Scientific evidence for clinical practice is warranted.”
BackgroundSmyczyńska, J., Stawerska, R., Lewiñski, A., & Hilczer, M. (2014) · Endokrynologia Polska · doi:10.5603/ep.2014.0046 · Cited by 17
Evaluation of Endocrine Function
Guber, H. A., & Farag, A. F. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0974-2.00024-5 · Cited by 19
Deutschbein, T., Bidlingmaier, M., Schopohl, J., Strasburger, C. J., & Petersenn, S. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0668 · Cited by 16
Vitamin D in children with growth hormone deficiency due to pituitary stalk interruption syndrome
Delecroix, C., Brauner, R., & Souberbielle, J. (2018) · BMC Pediatrics · doi:10.1186/s12887-018-0992-3 · Cited by 15
Transsphenoidal surgery for pituitary adenomas: early results from a single center
Karamouzis, I., Caputo, M., Mele, C., Nuzzo, A., Zavattaro, M., Car, P., Panzarasa, G., Prodam, F., Marzullo, P., & Aimaretti, G. (2018) · HORMONES · doi:10.1007/s42000-018-0082-9 · Cited by 15
Individual sensitivity to growth hormone replacement in adults
Boguszewski, C. L. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09605-1 · Cited by 19
Clinical Excellence in Endocrinology
Baum, H. B. A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00916 · Cited by 16
Appelman‐Dijkstra, N. M., Rijndorp, M., Biermasz, N. R., Dekkers, O. M., & Pereira, A. M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1086 · Cited by 14
Dutta, D., Dharmshaktu, P., Aggarwal, A., Gaurav, K., Bansal, R., Devru, N., Garga, U., & Kulshreshtha, B. (2016) · Journal of Postgraduate Medicine · doi:10.4103/0022-3859.183170 · Cited by 20
Kam, R. K. T., Ho, C. S., & Chan, M. H. M. (2016) · PubMed Central · Cited by 14
Sports-Related Repetitive Traumatic Brain Injury: A Novel Cause of Pituitary Dysfunction
Sezgin Caglar, A., Tanriverdi, F., Karaca, Z., Unluhizarci, K., & Kelestimur, F. (2019) · Journal of Neurotrauma · doi:10.1089/neu.2018.5751 · Cited by 14
Prevalence of hypopituitarism and quality of life in survivors of post‐traumatic brain injury
Meriem, B., Donaldson, M., Labassen, M., Cherfi, L., Nebbal, M., Haffaf, E. M., Abdennebi, B., Guenane, K., Kemali, Z., & Kablia, S. O. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.146 · Cited by 17
“21 ± 10 (18-65) years with moderate TBI (GCS 8-13) in 100 (75.”
Role of circulating molecules in age-related cardiovascular and metabolic disorders
Hsiao, Y., Shimizu, I., Yoshida, Y., & Minamino, T. (2022) · Inflammation and Regeneration · doi:10.1186/s41232-021-00187-2 · Cited by 16
Daniel, A., Ezzat, S., & Greenblatt, E. M. (2012) · Case Reports in Endocrinology · doi:10.1155/2012/356429 · Cited by 14
Zirilli, L., Orlando, G., Carli, F., Madeo, B., Cocchi, S., Diazzi, C., Carani, C., Guaraldi, G., & Rochira, V. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0829 · Cited by 14
Primary Pituitary Lymphoma As Rare Cause Of A Pituitary Mass And Hypopituitarism In Adulthood
Caputo, M., Prencipe, N., Bisceglia, A., Bona, C., Maccario, M., Aimaretti, G., Grottoli, S., & Gasco, V. (2020) · Endocrine Practice · doi:10.4158/ep-2020-0286 · Cited by 14
GH Use in the Transition of Adolescence to Adulthood
Mauras, N. (2010) · Endocrine development · doi:10.1159/000316131 · Cited by 18
Growth hormone treatment in adults with growth hormone deficiency: The transition
Molitch, M. E. (2011) · Journal of Endocrinological Investigation · doi:10.1007/bf03347046 · Cited by 14
Self-citationRegulation of bone mass in endocrine diseases including diabetes
Higham, C., & Abrahamsen, B. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101614 · Cited by 15
Endocrine immune-related adverse effects of immune-checkpoint inhibitors
Trevisani, V., Iughetti, L., Lucaccioni, L., & Predieri, B. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2256841 · Cited by 18
Once upon a time: the glucagon stimulation test in diagnosing adult GH deficiency
Cuboni, D., Caputo, M., Ghigo, E., Aimaretti, G., & Gasco, V. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02322-5 · Cited by 13
Testing for growth hormone deficiency in adults
Kargi, A. Y., & Merriam, G. R. (2012) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32835430da · Cited by 14
Self-citationGH deficiency in adult survivors of childhood cancer
Felicetti, F. C., Fortunati, N., Arvat, E., & Brignardello, E. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.11.007 · Cited by 14
Bonert, V. S., & Melmed, S. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804169-7.00004-0 · Cited by 21
Dutta, D., Mahajan, K., Kumar, M., & Sharma, M. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102421 · Cited by 13
Adult Growth Hormone Deficiency: Diagnostic and Treatment Journeys From the Patients’ Perspective
Hoffman, A. R., Mathison, T., Andrews, D., Murray, K., Kelepouris, N., & Fleseriu, M. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac077 · Cited by 16
TREATMENT OF ADULT GROWTH HORMONE DEFICIENCY: WHO, WHY AND HOW? A REVIEW.
Alexopoulou, O., Abs, R., & Maiter, D. M. (2010) · Acta Clinica Belgica · doi:10.1179/acb.2010.002 · Cited by 14
Kinoshita, Y., Tominaga, A., Usui, S., Arita, K., Sakoguchi, T., Sugiyama, K., & Kurisu, K. (2012) · Endocrine Journal · doi:10.1507/endocrj.ej12-0230 · Cited by 13
Beck‐Peccoz, P., Minuto, F. M., Leal‐Cerro, A., Zabransky, M., & Stalla, G. K. (2012) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018812444152 · Cited by 14
“com All adults with documented severe GHD are eligible for GH replacement therapy, and the goals of treatment are to correct the metabolic, functional and psychological abnormalities associated with adult GHD [Ho, 2007; Molitch et al. 2011].”
BackgroundMethodInfluentialFleck, S. K., Wallaschofski, H., Rosenstengel, C., Matthes, M., Kohlmann, T., Nauck, M. A., Schroeder, H. W. S., & Spielhagen, C. (2013) · BMC Endocrine Disorders · doi:10.1186/1472-6823-13-51 · Cited by 13
Carmichael, J. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804169-7.00010-6 · Cited by 14
Fujio, S., Hirano, H., Yamashita, M., Usui, S., Kinoshita, Y., Tominaga, A., Hanada, T., Yamahata, H., Tokimura, H., Hanaya, R., et al. (2017) · Neurologia medico-chirurgica · doi:10.2176/nmc.oa.2017-0079 · Cited by 13
Biomarkers of GH action in children and adults
Schilbach, K., Olsson, D. S., Boguszewski, M. C. D. S., Bidlingmaier, M., Johannsson, G., & Jørgensen, J.-O. L. (2018) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2018.03.005 · Cited by 16
EGF-GH Axis in Rat Steatotic and Non-steatotic Liver Transplantation From Brain-dead Donors
Álvarez‐Mercado, A. I., Negrete-Sánchez, E., Gulfo, J., León, C. G. A.-D., Casillas-Ramírez, A., Cornide‐Petronio, M. E., Bujaldon, E., Rotondo, F., Gracia‐Sancho, J., Jiménez‐Castro, M. B., et al. (2019) · Transplantation · doi:10.1097/tp.0000000000002636 · Cited by 15
Stimulated GH levels during the transition phase in Prader–Willi syndrome
Grugni, G., Marzullo, P., Delvecchio, M., Iughetti, L., Licenziati, M. R., Osimani, S., Ragusa, L., Salvatoni, A., Sartório, A., Stagi, S., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01450-y · Cited by 15
Yuen, K. C. J. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1455 · Cited by 13
Monzani, M. L., Pederzoli, S., Volpi, L., Magnani, E., Diazzi, C., & Rochira, V. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab002 · Cited by 14
Primary and Secondary Hypogonadism
Santi, D., & Corona, G. (2017) · Endocrinology · doi:10.1007/978-3-319-44441-3_24 · Cited by 17
Gundgurthi, A., Garg, M. K., Nair, V., Pakhetra, R., Das, S., Sharma, S., Dutta, M. K., Kharb, S., & Kapoor, R. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.117248 · Cited by 13
Dullaart, R. P. F., Schols, J. L., van der Steege, G., Zelissen, P. M. J., Sluiter, W. J., & van Beek, A. P. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03196.x · Cited by 14
Boschetti, M., Agosti, S., Albanese, V., Casalino, L., Teti, C., Bezante, G. P., Brunelli, C., Albertelli, M., & Ferone, D. (2016) · Endocrine · doi:10.1007/s12020-016-0951-4 · Cited by 17
Beck‐Peccoz, P., Höybye, C., Murray, R. D., Şimşek, S., Zabransky, M., Zouater, H., & Stalla, G. K. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-019-0464-2 · Cited by 13
Gibney, J., Healy, M., Smith, T. P., & McKenna, T. J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0154 · Cited by 16
Long-term effects of GH therapy in adult patients with Prader-Willi syndrome: a longitudinal study
Grugni, G., Sartório, A., Soranna, D., Zambon, A., Grugni, L., Zampino, G., & Crinò, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1198616 · Cited by 12
Bioletto, F., Sibilla, M., Gasco, V., Ghigo, E., & Grottoli, S. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02356-9 · Cited by 14
“For instance, patients that are not candidate for GH replacement therapy might not be tested for GHD, which may thus remain undiagnosed in some cases [42, 43].”
BackgroundGrowth hormone deficiency: diagnosis and therapy in children
Bozzola, M., & Meazza, C. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.09.69 · Cited by 16
Brigante, G., Diazzi, C., Ansaloni, A., Zirilli, L., Orlando, G., Guaraldi, G., & Rochira, V. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0961 · Cited by 12
Cecchi, C. R., Higuti, E., Oliveira, N. A. D. J., Lima, E. R., Jakobsen, M., Dagnaes-Hansen, F., Gissel, H., Aagaard, L., Jensen, T. G., Jorge, A. A. L., et al. (2014) · Current Gene Therapy · doi:10.2174/1566523214666140224112039 · Cited by 12
Metadata
- Authors
- Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L.
- Affiliations
- Northwestern University (US)
- University of North Carolina at Chapel Hill (US)
- University of Washington (US)
- University of Virginia (US)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-06
- Volume
- 96
- Issue
- 6
- Pages
- 1587-1609
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2090627812
- Semantic Scholar
- 82180f0f73f275a6a0e865c2c46af465e9dc1fc8
- Cited by
- 1,047
- References
- 207
- Citations by year
- 2026: 31 · 2025: 43 · 2024: 46 · 2023: 53 · 2022: 59 · 2021: 61 · 2020: 59 · 2019: 59 · 2018: 64 · 2017: 56 · 2016: 66 · 2015: 63 · 2014: 61 · 2013: 75 · 2012: 42
- FWCI
- 57.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- adult growth hormone deficiency, growth hormone therapy, body composition, exercise capacity, skeletal integrity, quality of life, treatment risks and benefits
- MeSH terms
- Adult, Dwarfism, Pituitary, Humans, Evidence-Based Medicine, Human Growth Hormone, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.